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Abstract
Purpose This study aims to compare endosaccular flow disruptor (EFD) for treatment of basilar tip aneurysm (BTA) with coiling
in terms of safety and efficacy.
Methods We retrospectively reviewed patients treated with an EFD for BTAs at our institution between 2013 and 2019 to
standard coiling from the same period (control group). Patient demographics, aneurysm characteristics, procedural data, com-
plications and clinical and angiographic outcome were compared between groups.
Results Twenty-three (56%) patients were treated with an EFD and eighteen (44%) patients were treated with coiling. Average
aneurysm size was 8 mm in the EFD group and 6.9 mm in the coiling group, respectively (P = 0.2). Average fluoroscopy time,
treatment DAP and air kerma were 33 min, 76 Gycm2 and 1.7 Gy in the EFD group and 81 min, 152 Gycm2 and 3.8 Gy in the
coiling group, respectively (P < 0.001). In the EFD group, clinically relevant thromboembolic complications occurred in one
patient (4%) vs. in 5 patients (28%) in the coiling group (P = 0.07). In each group, 4 patients had an unfavourable outcome at
discharge (P = 0.7). Adequate occlusion rates were 96% in the EFD group and 100% and coiling group. Six (26%) patients were
prescribed long-term antiplatelet therapy in the EFD group vs. eleven (61%) patients in the coiling group (P = 0.02).
Conclusion Both treatment concepts provided similar technical success and safety. However, procedure time, radiation exposure
and a need for long-term antiaggregation were lower with EFD.
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Introduction
Endovascular occlusion is the treatment of choice for basilar
tip aneurysm (BTA). However, the anatomy of the basilar
apex and the often broad-based configuration of BTAs may
make treatment challenging.
A variety of different techniques has been developed to
enable safe and successful endovascular treatment of bifurca-
tion aneurysms including balloon and stent assistance in var-
ious configurations and recently developed neck-bridging
devices [1, 2]. However, all these techniques require several
steps, making the procedure complex and prone to device- and
procedure-related complications.
The Woven EndoBridge (WEB; Microvention/Terumo,
Aliso Viejo, CA, USA) is deployed completely endosaccular
in order to reduce the inflow into the aneurysm at the level of
the neck, thus leading to thrombus formation and potentially
shrinkage of the aneurysm sac. The technical success and safety
of WEB was supported by several studies resulting in wide-
spread use for both ruptured and unruptured aneurysms [3–7].
Recently, the Contour device (Cerus Endovascular,
Fremont, CA, USA) was introduced; similar to WEB, it is
designed to disrupt the inflow into the aneurysm sac at the level
of the neck of the aneurysm. The device is composed of nitinol
wires forming a dual-layer mesh and has a flat, disc-like con-
figuration when unconstrained. Once optimally deployed at the
aneurysm neck, it adopts a conical shape, covering the lower
part of the aneurysm and the neck [8, 9].
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Several studies compared different techniques for the treat-
ment of intracranial aneurysms [10, 11]. However, to the best
of our knowledge no studies are available comparing the safe-
ty and efficacy of different endovascular techniques specifi-
cally in BTAs.
In the current study, we compared endosaccular flow dis-
ruption to conventional methods for treatment of BTAs in
terms of safety and efficacy.
Material and methods
We retrospectively reviewed consecutive patients who
underwent endovascular treatment for saccular BTA at our
institution between January 2013 and December 2019. Local
ethics committee approved this study and requirement of pa-
tient consent was waived because of the retrospective nature
of the study.
The inclusion criteria were defined as (1) successful
endovascular treatment of a BTA using an endosaccular flow
disruptor and (2) successful endovascular treatment of a BTA
by stand-alone coiling, balloon-assisted coiling (BAC) or stent-
assisted coiling (SAC).
Cases fulfilling the first inclusion criterion formed the
“endosaccular flow disruptor (EFD) group” and the rest
formed the “coiling group”.
Exclusion criteria were (1) recurring aneurysms and (2) aneu-
rysms treated with an endosaccular flow disruptor using stent
assistance.
Procedure
The technique chosen for aneurysm occlusion was left to the
discretion of the neurointerventionalist. Generally, stand-
alone coiling or WEB was used as standard approach. In
wide-necked aneurysms, anatomical features requiring stent
or balloon assistance or the Contour were as follows: irregular
shape, daughter sacs, low aspect ratio (≤ 1.3) or very small or
large aneurysm size (i.e. not covered by the available sizes of
WEB). Configuration and size of the posterior cerebral arter-
ies was also a factor when choosing between BAC and SAC
or EFD.
All procedures were performed on a biplane angiosuite
(Siemens, Erlangen, Germany) under general anaesthesia. A
bolus of intravenous heparin (5000 IU) was administered after
groin puncture, followed by smaller doses to maintain an ac-
tivated clotting time (ACT) of 2 to 3 times of the baseline.
After navigating a guiding catheter into the larger vertebral
artery, the aneurysm was catheterized with a dedicated
microcatheter over a 0.014-in. microguidewire.
EFD group
Endosaccular flow disruptors that have been used were WEB
single layer (SL), WEB single-layer sphere (SLS) and the
Contour device.
WEB was delivered through a VIA microcatheter
(Microvention/Terumo, Aliso Viejo, CA, USA). The appropriate
WEB size was selected to slightly exceed the aneurysm width as
recommended by the manufacturer. Contour was delivered
through a Headway 27 microcatheter (Microvention/Terumo,
Aliso Viejo, CA, USA).
Coiling group
Coiling was performed through a 0.017-in. SL-10
microcatheter (Stryker, Kalamazoo, MI, USA). In all BAC
procedures, Sceptre balloons (Microvention/Terumo, Aliso
Viejo, CA, USA) were used.
For SAC, single-stenting or Y- and T-stenting techniques
were used. Stent types implanted were Solitaire AB
(Covidien, Irvine, CA, USA), Neuroform EZ and Atlas
(Stryker, Kalamazoo, MI, USA), LEO Baby (Balt,
Montmorency, France) or LVIS Jr. (Microvention/Terumo,
Aliso Viejo, CA, USA).
In one case, the eCLIPs (Endovascular Clip System; Evasc
Medical Systems Corp., Vancouver, BC, Canada) device was
used to reconstruct the neck.
Antiaggregation therapy
Unruptured aneurysms
Patients scheduled for elective treatment with an EFD or a
stent were premedicated with acetylsalicylic acid (ASA)
100mg and clopidogrel 75mg daily, started 5 to 7 days before
treatment. In cases treated with EFD, ASA monotherapy was
continued for a minimum of 4 weeks. If a stent was used, a
dual antiplatelet regimen (ASA 100mg and clopidogrel 75mg
daily) was required for 4–6 months after the procedure,
followed by life-long ASA 100 mg/day.
In cases treated with stand-alone or balloon-assisted
coiling, depending on the size of the neck and the protrusion
of coil mass into the parent artery, ASA monotherapy was
continued for a minimum of 3 months.
Ruptured aneurysms
In patients with ruptured aneurysms treated with SAC,
tirofiban (Aggrastat; Merck, New York, USA) was adminis-
tered during the procedure and usually continued for 12 h after
the procedure, followed by a loading dose of ASA (500 mg)
and clopidogrel (300 mg). Antiplatelet therapy was continued
as described above for unruptured aneurysms.
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In EFD or stand-alone coiling cases with wide neck and
device protrusion into the parent vessel, short-term monother-
apy with ASAwas considered after securing the rupture point.
If acute thrombosis occurred during the procedure, intrave-
nous tirofiban was started irrespective of the rupture status,
usually continued for 12 h after the procedure and followed
by a double antiplatelet therapy as described above.
Antiplatelet therapy ending within the first 6 months after
the procedure is considered short term and therapy continuing
more than 6 months is considered long-term therapy.
Drug response was tested in all patients (Multiplate®
Analyser; Roche, Basel, Switzerland). An insufficient re-
sponse to either drug was managed either by dose escalation
or substitution with an agent such as prasugrel.
Data collection
Patient demographics, aneurysm characteristics, procedural data,
procedure-related complications and clinical and angiographic
outcome at follow-up were retrospectively obtained from the
medical charts. Procedural radiation exposure was measured as
fluoroscopy time, air kerma (Gy) and dose area product (DAP,
Gycm2). The Fisher scale (1: no subarachnoid (SAH) or intra-
ventricular haemorrhage (IVH); 2: diffuse thin SAH without
IVH; 3: thick SAH without IVH; 4: IVH or intracerebral haem-
orrhage with or without SAH) was used to evaluate the extent of
SAH on CT and theWFNS (World Federation of Neurosurgical
Societies) grading system (1: GCS (Glasgow Coma Scale) 15
without deficit; 2: GCS 13–14 without deficit; 3: GCS 13–14
with focal neurological deficit; 4: GCS 7–12 with or without
deficit; 5: GCS < 7 with or without deficit) was used to evaluate
the clinical status.Wide neckwas defined either as a neck >4mm
or an aspect ratio < 1.6. Clinical outcome was evaluated by the
modified Rankin Scale (mRS) before treatment and at discharge.
Unfavourable outcome was defined as mRS> 2.
Angiographic control and retreatment
Our follow-up protocol consists of angiographic controls at 6
and 24 months after the procedure using DSA (digital subtrac-
tion angiography) in the majority of cases and magnetic reso-
nance angiography (MRA) or computed tomography angiog-
raphy (CTA) in other cases. The Raymond-Roy occlusion
classification was used to assess aneurysm occlusion at
follow-up (grade I: complete occlusion; grade II: neck rem-
nant; grade III: aneurysm remnant). Complete occlusion and
neck remnants were defined as adequate occlusion.
Statistical analysis
Continuous variables were presented as means, percentages
and ranges. They were tested for normality using the
Shapiro-Wilk test and compared between the EFD group
and coiling group using the 2-sided unpaired Student t test
(for normally distributed data) and the Mann-Whitney U test
(for non-normally distributed data).
Categorical variables were expressed as names or numbers
with percentages and compared between the groups using the
χ2 and the Fisher exact test, when appropriate.
Univariate logistic regression analysis was performed to
test the predictive power of treatment type on short- and
long-term antiplatelet use and angiographic and clinical out-
come. A linear regression analysis was made to analyse the
relationship between aneurysm size, height, neck width or
aspect ratio and the amount of fluoroscopy time or radiation
exposure. All calculations were performed using SPSS soft-
ware Version 25.0 (IBM, Armonk, New York, USA). A P
value <0.05 was considered statistically significant.
Results
Patient and aneurysm characteristics
Forty-one patients who underwent endovascular treatment for
a saccular BTA between 2013 and 2019 were included.
Twenty-three (56%) patients were treated with an EFD and
eighteen (44%) patients were treated with other techniques.
The characteristics of patients and aneurysms from each group
are shown in Table 1. All SAHs were grade 4 according to the
Fisher scale. The medianWFNS score of SAH patients was 4.
Aneurysm treatment and procedural radiation
exposure
All but two cases were performed via transfemoral approach.
In two cases (one in each group), transbrachial approach was
selected because of chronic bilateral iliac artery occlusions.
Endovascular treatment techniques are presented in Table 2.
In three SAH patients (17%) from the coiling group,
endovascular treatment of an aneurysm at another location
(two anterior communicating artery and one superior cerebel-
lar artery (SCA) aneurysms) was necessary during the same
session as the BTA. All of themwere treated with coils. In one
SAH patient, BTA and the additional SCA aneurysm were
covered with the same stent and occluded with coils.
Procedural radiation doses and procedure times are report-
ed in Table 1. In the coiling group, after exclusion of the
patients with other aneurysms treated during the same session,
the average fluoroscopy time, DAP and air kerma dropped to
76 min, 145 Gycm2 and 3.7 Gy, respectively, maintaining the
significant difference from the EFD group.
According to linear regression analysis, there was no sig-
nificant relationship between aneurysm size, height, neck




In the EFD group, adverse events occurred in five WEB pa-
tients (21%). All of them were thromboembolic events and
happened in elective cases. However, only one of the patients
had a transient neurologic deficit and theMR Imaging showed
multiple embolic lesions in multiple vascular territories.
Others were clinically silent.
In the coiling group, complications occurred in seven pa-
tients (39%). Six (33%) of them were thromboembolic events
(5 in SAH patients). In only 3 (17%) patients thromboembolic
complications were clinically relevant. One of them presented
itself 4 months after the intervention after cessation of
clopidogrel. All others occurred were periprocedural. In one
elective case, a LEO Baby 3/25 stent was positioned at the
level of the aneurysm neck initially but dislocated dur-
ing deployment. It was then safely placed in the distal
cervical segment of the vertebral artery. The aneurysm
was subsequently coiled with stent assistance using two
LVIS Jr. stents in T-configuration. The patient showed
no postoperative neurological deficit.
There was no statistical significance between two
groups regarding the thromboembolic complication rates
(P = 0.5).
Including only clinically relevant thromboembolic
complications, the rates dropped down to 4% (1/23) and
17% (3/18) in the EFD group and coiling group, respec-
tively. The difference was still not statistically significant
(P = 0.3).
No haemorrhagic event was recorded.
Clinical outcome
In each group, 4 patients (17% in the EFD group and 22% in
the coiling group) had an unfavourable outcome at discharge
(P = 0.7). From the four patients, two had SAH in the EFD
group and all had SAH in the coiling group.
In the EFD group, two of the SAH patients (9%) died; one
due to multiple cerebral infarctions because of intractable ce-
rebral vasospasm and the other one due to multi-organ failure.
Remaining cases with unfavourable outcome had already high
mRS scores because of pre-existing comorbidities.
In the coiling group, one patient (5%) presented with SAH
and treated with SAC died because of haemorrhagic transfor-
mation of a large posterior cerebral artery infarction due to
stent occlusion. Other patients had unfavourable scores be-
cause of SAH-related incidences.
Table 1 Characteristics of
patients, aneurysms and
procedures and list of
complications and follow-up
EFD (n = 23) Coiling (n = 18) P values
Mean age (range) 61 (35–81) 58 (40–76) 0.5
Male sex 8 (35%) 6 (33%) 0.9
Ruptured aneurysms 4 (17%) 9 (50%) 0.02
Mean size in mm (range) 8 (3.1–16) 6.9 (3.1–12) 0.2
Mean neck size in mm (range) 4.4 (2.3–6.8) 3.9 (2.1–6.7) 0.1
Wide-necked aneurysms 20 (87%) 12 (67%) 0.1
Mean aspect ratio (range) 1.4 (0.9–2.8) 1.5 (0.7–2.8) 0.7
Mean fluoroscopy time in min (range) 33 (8–108) 81 (30–143) < 0.001
Mean dose area product in Gycm2 (range) 76 (11–199) 152 (58–298) < 0.001
Mean air kerma in Gy (range) 1.7 (0.3–5) 3.8 (1.5–7.8) < 0.001
Thromboembolic complications 5 (21%) 6 (33%) 0.5
Clinically relevant thromboembolic complications 1 (4%) 3 (17%) 0.3
Unfavourable clinical outcome 4 (17%) 4 (22%) 0.7
Adequate aneurysm occlusion 22 (96%) 18 (100%) 1
Retreatment 1 (4%) 0 (0%) 1
Short-term antiplatelet medication 16 (70%) 12 (67%) 0.8
Long-term antiplatelet medication 6 (26%) 11 (61%) 0.02
Table 2 Endovascular treatment techniques
Treatment group Treatment method Number of patients
EFD WEB 18 (78%)
Contour 4 (17%)
WEB + coils 1 (5%)
Coiling Coiling 7 (39%)
BAC 4 (22%)
SAC 6 (33%)
Neck-bridging device 1 (6%)
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Angiographic outcome
Median follow-up was 8 months (min 1, max 60). Eight pa-
tients (5 in the EFD group and 3 in the coiling group) were lost
to follow-up. Sixteen patients had no DSA, but MR or CT
angiography at follow-up. In the EFD group, adequate occlu-
sion rate was 96% (19 complete occlusions, 3 neck remnants
and 1 aneurysm remnant). Only one patient (4%) who was
initially treated with a WEB device showed recurrence after
11 months and was retreated with BAC. In the coiling group,
adequate occlusion was obtained in 100% of the patients (16
complete occlusions and 2 neck remnants). Adequate occlu-
sion rates were not significantly different between the two
groups (P = 1).
According to univariate logistic regression analysis, treatment
type was not predictive of angiographic and clinical outcome.
Antiplatelet medication
Antiaggregation status of patients at baseline, < 6 months
and > 6 months after the procedure is presented in Table 3.
In short term, 16 (70%) patients in the EFD group took single
or double antiplatelets vs. 12 (67%) patients in the coiling
group (P = 0.8). Six (26%) patients were prescribed long-
term antiplatelet therapy in the EFD group vs. eleven (61%)
patients in the coiling group (P = 0.02). Two patients in the
EFD group took double antiplatelet medication for 6 months
after the procedure (9%) vs. eight (44%) patients in the coiling
group (P = 0.01). However, treatment type was not a predictor
of short- or long-term antiplatelet therapy.
Discussion
In the current study, we compared endosaccular flow disruption
with conventional methods (stand-alone coiling, BAC and SAC)
for treatment of BTAs in terms of safety and efficacy.We did not
find a significant difference between the treatment groups regard-
ing the thromboembolic complication rate, as well as the clinical
and final angiographic outcome. However, procedural fluorosco-
py time and radiation exposure were significantly lower in
patients who were treated with endosaccular flow disruptor de-
vices. In addition, they were significantly less likely to have an
indication to take antiplatelets in long term.
BTAs are special among cerebral aneurysms in several re-
spects: surgical treatment is usually not an option, but due to the
often broad-necked configuration (up to 60% according to
Lozier et al.), pure coiling is also in many cases not possible
[12–16].
Rates of recurrence after stand-alone coiling have been
reported to be as high as 25 to 30% in large and wide-
necked aneurysms [17, 18]. While additional devices such as
balloons, self-expanding stents or neck-bridging devices may
improve the coil packing density and thereby the efficacy of
endovascular coil embolization on one hand, they increase the
complexity of the procedure on the other hand, which in turn
may increase the risk for complications [19–21]. Furthermore,
antiplatelet medication is mandatory for all patients after any
stent treatment, which may complicate subsequent surgical
procedures, especially for patients after SAH [21, 22].
The WEB and Contour devices represent a completely dif-
ferent concept: different from stents and intraluminal flow
diverter stents, these dense-meshed devices are placed
completely in the aneurysm sac and aim to disrupt the blood
flow entering and exiting the sac at the level of the neck in
order to promote stagnation and thrombus formation. The
WEB device proved efficacy and safety in multiple prospec-
tive and retrospective multi-centred studies, especially in the
treatment of ruptured and wide-necked aneurysms [3–7].
Currently, there are two studies that compare stand-alone
coiling and WEB treatment, as well as SAC and WEB [10,
11]. Kabbasch et al. included aneurysms at all anatomical
locations in the evaluation. They reported a significantly
higher complication rate in the SAC group (14/66 aneurysms,
21%) compared with the WEB group (8/66 aneurysms, 12%).
The complete occlusion rate was higher in aneurysms treated
with theWEB device (41/47, 87%) compared with aneurysms
treated by coiling (31/51, 61%) and similar to those treated by
SAC (55/66, 84% vs. 56/66, 85%). Retreatment rates were
significantly higher in the coiling group (9/51, 18% vs. 2/47,
4%) and similar between the WEB (7/66, 11%) and the SAC
(8/66, 12%) group.
Table 3 Antiplatelet regimen at
baseline, < 6 months and >
6 months after the procedure
Number of antiplatelets EFD group Coiling group
Treatment duration Treatment duration
Baseline < 6 months > 6 months Baseline < 6 months > 6 months
0 19 (83%) 7 (30%) 17 (74%) 18 (100%) 6 (33%) 7 (39%)
1 4 (17%) 14 (61%) 6 (26%) 0 (0%) 4 (22%) 10 (55%)
2 0 (0%) 2 (9%) 0 (0%) 0 (0%) 8 (45%) 1 (6%)
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Other potential advantages of the EFDs, such as potential
reduction of procedural fluoroscopy time and radiation dose
have, however, not been addressed yet.
Complications
The rate of clinically relevant thromboembolic events was
higher in the coiling group (17%) than in the EFD group
(4%), however without statistical significance (P = 0.3). The
thromboembolic complication rate in the EFD group was in
compliance with the literature [3–7].
The coiling group showed a higher rate than previously
reported. In large coiling series including only BTAs, throm-
boembolic complication rates varied from 6 to 12% [12–14,
16, 17]. Explanations might be small size of our study group
and significantly higher numbers of ruptured cases in the
coiling group.
Radiation exposure
Radiation exposure in endovascular aneurysm therapy has so
far received little attention. Differences in individual aneu-
rysm geometry and vessel anatomy, as well as in experience
levels and treatment preferences of neurointerventionalists,
make a comparison of radiation exposure and a definition of
acceptable thresholds difficult.
Direct measurement of the absolute entrance skin doses is not
practicable and therefore surrogate markers such as DAP
(Gycm2) and air kerma (Gy) are usually used [23–27].
The threshold for deterministic skin damage such as ery-
thema or hair loss is considered to be at 2 to 3 Gy [27, 28].
Struelens et al. proposed a DAP trigger level of 220–330
Gycm2 as a threshold for skin effects in cerebral embolization
procedures [26].
In a study of Peterson et al. [23] including 702
neurointerventional procedures, skin entrance doses exceed-
ing 2 Gy occurred in 73% of procedures. After almost 40% of
them, patients reported changes of their skin or hair and 30%
of the changes were permanent. Increasing skin dose was
significantly associated with permanent hair loss.
Ihn et al. evaluated 371 aneurysm treatments nationwide in
2015 [25]. Total mean DAP, air kerma and fluoroscopy time
were 219 Gycm2, 3.3 Gy and 51 min, respectively. The re-
ported radiation exposure exceeded the cited threshold values
but the patients were not specifically followed up for
radiation-induced skin or hair changes.
Data regarding the radiation exposure in treatment of intra-
cranial aneurysms with the WEB device is available from a
prospective multi-centre study including 150 aneurysms.
Arthur et al. reported an average procedural fluoroscopy time
of 30min and an average air kerma of 2.7 Gy [7]. Our findings
in the EFD group (33 min, 76 Gycm2, 1.7 Gy) were compa-
rable with those figures. Both the procedural time and the
radiation dose were higher in the coiling group (81 min, 152
Gycm2, 3.8 Gy); however, these numbers are still in compli-
ance with the literature [24, 25].
Technical simplicity is certainly the major reason for faster
procedure times and low radiation exposure in treatments with
EFD. SAC, for example, requires multiple steps including
catheterization of the distal parent vessel, stent deployment,
catheterization of the aneurysm sac and filling it with multiple
coils. Usually several control injections are needed. In EFDs,
in particular for WEB, exact measurements and device selec-
tion prior to the procedure are necessary, but the procedure
itself after catheterization consists only of device deployment.
Angiographic outcome
In our study group, both treatment groups had similar rates of
adequate occlusion (22/23, 96% in the EFD group vs. 18/18,
100% in the coiling group). Retreatment was necessary only
in one patient after WEB and in none of the aneurysms treated
with other techniques.
In general, complete occlusion seems to be less frequently
achieved in BTAs and retreatment is more often necessary when
comparedwith other aneurysm localizations [14, 17, 29, 30]. In a
systematic review including 226 coiled BTAs, Lozier et al. [16]
reported an initial complete or near-complete aneurysm occlu-
sion in 88% of the patients; however, the recanalization rate was
26% with a 0.7% annual risk for recurrent haemorrhage. In an-
other study by Henkes et al. [12] including coil embolization of
316 BTAs, recurrence, retreatment and recurrent haemorrhage
rates were found to be as high as 35%, 15% and 5%, respective-
ly. After the initial embolization procedure, a 90 to 100% occlu-
sion rate was achieved in 86% of the aneurysms.
In the cumulative population of three prospective WEB
studies, Pierot et al. observed an adequate occlusion rate of
81% and retreatment rate of 9% at 2-year follow-up [4]. Just as
in our study, Kabbasch et al. found equal adequate occlusion
rates between WEB and SAC (94%) in their series including
66 wide-necked bifurcation aneurysms from each group [11].
Antiplatelet medication
So far, there has been no standard regarding the use of antiplatelet
medication after endovascular aneurysm treatment. This applies
to stand-alone coiling, as well as to SAC and EFD. The peri- and
postprocedural antiplatelet regimen is usually left to the
neurointerventionalists’ discretion. In cases treated without stent
assistance, usually a short-term single or double antiplatelet ther-
apy is given, especially in wide-necked aneurysms or when the
parent artery or incorporated vessels are compromised by the
implant. In patients treated by stent-assisted coiling, a short-
term double antiplatelet therapy is required.
In the multi-centred prospective WEB studies, antiplatelet
therapy was not mandatory. However, the majority of the
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patients received double antiplatelet medication prior and dur-
ing the procedure (69% in the WEB-IT study and 45% in the
WEBCAST and French Observatory group) [4, 7].
In the WEB-IT study, 74% of patients had short-term anti-
platelet therapy in keeping with our results (70%) from the EFD
group. In the coiling group, the overall rate was similar (67%),
but the percentage of patients using double antiplatelets was
higher (67% in the coiling vs. 12% in the EFD group) [7].
In long term, patients in the coiling group (61%) were signif-
icantly more often prescribed antiplatelets than in the EFD group
(26%). As a comparison, that rate was 48% in theWEB-IT study
group [7]. Unfortunately, we could not find any comparable
study reporting antiaggregation use in coiled aneurysms.
Limitations
Major drawbacks of this study are mainly its retrospective,
single-centred and non-randomized nature and the relatively
small number of included cases. The method chosen to occlude
the aneurysms was based on the discretion of the
neurointerventionalist and various factors such as the surgeon’s
experience, rupture status or patients’ comorbidities may have
influenced these decisions. Thus, we cannot exclude a potential
selection bias, because some of the aneurysm in the coiling group
may have had an unfavourable configuration for EFD.
Furthermore, heterogeneity of the occlusion techniques used
(stand-alone, balloon- or stent-assisted coiling) and larger propor-
tion of ruptured aneurysms among the coiling group might con-
found a meaningful comparison between two main treatment
strategies.
Only one patient was included who was treated with a
dedicated bifurcation stent (eCLIPs) and our data thus does
not allow any conclusion about treatment with these devices.
Conclusion
Our data provides the first comparative analysis of
endosaccular flow disruption with other treatment methods
for endovascular management of basilar tip aneurysms.
Both treatment concepts provided similar technical success
and safety. However, procedural time, radiation exposure and
the indication for long-term antiaggregation were significantly
in favour of EFD. It may thus be argued, that with both strat-
egies deemed suitable, EFD should be preferred.
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